India’s biotechnology sector has grown into one of the largest in the Asia-Pacific region, spanning pharmaceuticals, agriculture, genomics, diagnostics, and marine bioprospecting. Much of this expansion traces to deliberate government policy: initiatives like Make in India, Startup India, and the establishment of the Biotechnology Industry Research Assistance Council (BIRAC) built a foundation for nurturing innovation and entrepreneurship across the country. But the story is more textured than a simple growth narrative, with some sectors delivering on early promise while others face stagnation, regulatory friction, or intellectual property bottlenecks that slow commercialization.
The Policy Infrastructure Behind the Growth
India’s biotech ecosystem did not emerge organically. It was deliberately seeded through a series of government programs designed to bridge the gap between laboratory research and marketable products. BIRAC, operating under the Department of Biotechnology, has been central to this effort. The council has established 60 bio-incubation centers across the country, providing startups with lab space, mentorship, and early-stage funding that would otherwise be inaccessible to small teams working on unproven technologies.1PubMed Central. Contributions of biotechnology industries of India to global bioeconomy: an overview
More recent policy moves have tried to push the ecosystem further. The BioE3 policy (focused on bio-economy, bio-energy, and bio-environment) and the Research Development and Innovation Fund aim to strengthen technology-driven development beyond the incubation stage, addressing the so-called “valley of death” where promising lab results fail to become viable businesses.2PubMed Central. Bioeconomy in India: Policy, Prospects and Perspective The idea is that creating incubators was necessary but not sufficient. Startups also need help navigating regulatory approvals, scaling manufacturing, and accessing global markets.
Where the Hubs Are
Biotech activity in India is not evenly distributed. A handful of cities have emerged as concentrated hubs, each with a slightly different character. Hyderabad’s Genome Valley is the most recognizable cluster, housing hundreds of life sciences companies alongside government research institutes. The city’s strength is in biopharmaceuticals, particularly vaccine manufacturing and biosimilars, and it benefits from proximity to major contract research organizations.
Bangalore functions as the broader life sciences and IT convergence point. Many bioinformatics firms and biotech startups sit alongside the city’s massive software industry, and the cross-pollination between computational expertise and biology has been productive. Pune has a dense network of academic institutions and research labs that feed into its growing biotech corridor. The National Capital Region around Delhi hosts several major government research bodies, including the Institute of Genomics and Integrative Biology, which has driven some of India’s most visible genomics work.
Beyond these established centers, smaller hubs are developing. Chennai and its surrounding Tamil Nadu coast have become important for marine biotechnology. Ahmedabad and Chandigarh have growing biotech parks. The government has actively tried to spread capacity beyond the traditional metros through the bio-incubation network, though gravity still pulls talent and capital toward the big four cities.
Agricultural Biotech and the Complicated Bt Cotton Story
Bt cotton remains the only genetically modified crop widely adopted by Indian farmers, making it the single most important test case for agricultural biotechnology in the country. The first decade after its introduction in 2002 was broadly seen as a success: multiple studies documented higher yields and profit gains for adopters, and the technology spread rapidly across cotton-growing regions. That early success shaped the public narrative and influenced policy debates about whether to approve other GM crops.
The second decade tells a different story. Research in the Ballari district of Karnataka found that Bt cotton yields have stagnated, with a null effect on profits, and that crops have become more sensitive to pest pressure in recent years.3PubMed Central. Sustainable agriculture and GM crops: the case of Bt cotton impact in Ballari district of India The convergence in benefits between Bt and non-Bt cotton raises genuine questions about the long-term trajectory of GM technology for smallholder farmers. Part of the issue is biological: pests can evolve resistance to the Bt toxin, especially when refuge requirements are poorly enforced. Part is economic: seed costs rose even as the yield advantage shrank.
This does not mean agricultural biotechnology in India is a dead end. It does mean that the Bt cotton experience offers a more nuanced lesson than either side of the GM debate typically acknowledges. Early gains were real but not permanent, and the technology works best as part of an integrated pest management strategy rather than as a standalone solution. The ongoing political stalemate over Bt brinjal (eggplant), which was approved by regulators but placed under an indefinite moratorium in 2010, reflects how the mixed cotton results have fed public skepticism.
Genomics and the IndiGen Program
One of India’s most distinctive contributions to global biotechnology has been in population genomics. The IndiGen program, led by the CSIR-Institute of Genomics and Integrative Biology, sequenced the whole genomes of 1,029 healthy Indian individuals in its pilot phase. The effort generated a compendium of nearly 56 million single-allelic genetic variants from geographically distinct populations across the country.4Nucleic Acids Research. IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes
Why does this matter? Most of the world’s genomic reference databases are heavily skewed toward populations of European descent. When a doctor in India tries to interpret a patient’s genetic test using those databases, variants that are common and benign in Indian populations can show up as “novel” or “uncertain significance” simply because they were never catalogued. The IndiGenomes database, which is publicly accessible online, provides allele frequencies, variant annotations, and population-specific data that allow clinicians and researchers to contextualize genetic findings for Indian patients specifically.
The pilot phase was explicitly designed as a proof of concept, and larger sequencing efforts are underway. India’s genetic diversity is enormous, reflecting thousands of years of population structure shaped by geography, language groups, and endogamy. Capturing that diversity in reference databases is not just an academic exercise; it directly affects the accuracy of clinical genetic testing, pharmacogenomics (predicting how individuals respond to drugs), and rare disease diagnosis for over a billion people.
Diagnostic Innovations and Biosensors
India has a particular incentive to develop low-cost, portable diagnostic devices. The country’s healthcare infrastructure is unevenly distributed, with well-equipped urban hospitals coexisting alongside rural primary health centers that lack basic laboratory facilities. Point-of-care diagnostics that can deliver results without expensive equipment or cold chains are not a nice-to-have; they are a practical necessity.
Indian researchers have made progress on several fronts. Graphene-based biosensors developed by Indian teams have shown promise for detecting cancer biomarkers such as carcinoembryonic antigen, a marker used in monitoring colorectal and other cancers. Other groups have created multiwalled-carbon-nanotube platforms embedded in zinc oxide nanowires for detecting antigen-125, a marker for ovarian cancer. A paper-based biosensor using polymer and reduced graphene oxide composites was developed specifically to be cheaper, flexible, and more environmentally friendly than conventional alternatives.5Sensors International. Current status of point-of-care diagnostic devices in the Indian healthcare system with an update on COVID-19 pandemic
The COVID-19 pandemic accelerated interest and investment in this space. India’s scale-up of RT-PCR testing, rapid antigen kits, and eventually home testing drew on existing diagnostic research capacity and exposed gaps that are now being addressed. The broader trend is toward devices that can be manufactured domestically at price points accessible to public health programs, not just private hospitals.
Marine Bioprospecting Along India’s Coastline
India’s roughly 7,500-kilometer coastline and its marine biodiversity represent a largely untapped resource for drug discovery. Marine organisms, particularly microbes living in extreme or unusual environments, produce chemical compounds that land-based organisms do not, and some of these compounds have potent antimicrobial properties at a time when antibiotic resistance is a growing global crisis.
Research from the Rameswaram coastal region in Tamil Nadu illustrates what this approach looks like in practice. Scientists isolated 131 actinomycetes (a group of bacteria known for producing bioactive compounds) from marine samples. Roughly 85% of these isolates showed some degree of antagonistic activity against test pathogens. One strain, identified as Streptomyces bacillaris RAM25C4, demonstrated activity against methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant bacteria including Acinetobacter baumannii and Pseudomonas aeruginosa.6PubMed. Bioprospecting marine actinomycetes for multidrug-resistant pathogen control from Rameswaram coastal area, Tamil Nadu, India These are precisely the pathogens that the World Health Organization has flagged as priority targets for new antibiotic development.
Marine bioprospecting is still early-stage work. Finding a compound with lab activity against a pathogen is a long way from having a clinical antibiotic, and the pipeline from ocean sample to approved drug typically takes well over a decade. But India’s coastline gives it a natural advantage in sourcing novel organisms, and the intersection of marine microbiology and pharmaceutical research is an area where Indian institutions are building genuine expertise.
Bridging Traditional Medicine and Modern Drug Discovery
India’s traditional medical systems, including Ayurveda, Siddha, and Unani, represent thousands of years of empirical observations about medicinal plants, therapeutic formulations, and disease treatment. For a long time, these traditions and modern pharmaceutical research existed in parallel universes. That is changing as computational tools make it possible to investigate traditional remedies using the same analytical framework applied to any drug candidate.
Molecular docking, network pharmacology, and data mining can help identify the mechanisms of action behind traditional treatments, predict drug interactions, and flag potential lead compounds for further development.7Siddhant- A Journal of Decision Making. Integrating Indian Traditional Knowledge with Bioinformatics Instead of starting from scratch to screen millions of random compounds, researchers can begin with formulations that have centuries of observational data behind them, then use modern tools to understand which active ingredients are doing what at a molecular level.
The challenges are substantial. Standardization is a persistent problem: traditional preparations are often complex mixtures whose composition varies by region, practitioner, and source material. Intellectual property questions are thorny, especially when traditional knowledge that belongs to entire communities intersects with patent systems designed for individual inventors. And there is a real risk of biopiracy, where foreign entities patent derivatives of traditional knowledge without proper acknowledgment or benefit-sharing. India’s Traditional Knowledge Digital Library, which documents traditional formulations in patent-examiner-accessible formats, was created specifically to prevent such misappropriation by serving as prior art in patent challenges.
How Gene Technologies Are Regulated
India’s regulatory framework for genetically modified organisms dates to 1989, when the “Rules for the manufacture, use, import, export & storage of hazardous microorganisms, genetically engineered organisms or cells” were notified under the Environment (Protection) Act of 1986. These rules are implemented jointly by the Ministry of Environment, Forest and Climate Change, the Department of Biotechnology, and state governments through six competent authorities.8PubMed Central. Regulation of emerging gene technologies in India
The framework is supported by guidelines covering contained research, biologics, confined field trials, food safety assessment, and environmental risk assessment. In principle, this is a comprehensive system. In practice, the regulatory process is often criticized for being slow, opaque, and susceptible to political pressure. The Bt brinjal moratorium is the most prominent example: the Genetic Engineering Appraisal Committee approved the crop, but the environment minister imposed an indefinite moratorium after public consultations, effectively overriding the scientific review process. For newer technologies like CRISPR-based gene editing, there is ongoing debate about whether the 1989 rules, written decades before such tools existed, are adequate or need updating.
The regulatory question is not just academic. Companies and researchers deciding where to invest consider regulatory predictability alongside scientific talent and infrastructure. A system that is comprehensive on paper but unpredictable in practice can push innovation offshore or into less regulated spaces.
The Patent Bottleneck
Even when Indian biotech companies or researchers develop commercially viable innovations, getting patent protection is unusually difficult. An analysis of patent disposal trends across sectors found that biotechnology exhibits the lowest disposal rates alongside the highest rates of refusal and abandonment, in stark contrast to the chemical sector, which leads in both disposals and grants.9Industrial Biotechnology. Exploring Biotechnological Patent Disposal Trends in India: Sectoral Comparisons and Implications
Several factors converge to create this bottleneck. India’s patent law, particularly Section 3(d) of the Patents Act, sets a higher bar for biological and pharmaceutical inventions than many other countries, requiring proof of enhanced efficacy for new forms of known substances. Patent examiners handling biotech applications often face subject matter that is technically complex and rapidly evolving, leading to longer review times. And the biotech industry’s own tendency toward broad, speculative claims can trigger more rejections.
The practical consequence is that Indian biotech firms frequently face a choice between waiting years for domestic patent protection, filing abroad where disposal is faster, or proceeding without patent protection and relying on speed-to-market and trade secrets instead. None of these options is ideal. The patent system’s sluggishness for biotech applications is a genuine drag on commercialization, and the research suggests that sector-specific strategies for patent management may be needed rather than treating all technology domains the same way.
Biofuels and Industrial Applications
India’s interest in bioethanol reflects both energy security concerns and agricultural economics. The country imports a significant share of its crude oil, and domestically produced biofuels offer a partial hedge against price volatility and supply disruptions. The government’s ethanol blending program, which mandates mixing ethanol with petrol, has created a guaranteed market that incentivizes production.
Research efforts have focused on the full chain of bioethanol production: identifying suitable feedstocks (sugarcane molasses has been the traditional source, but agricultural residues and other lignocellulosic materials are being explored), developing efficient pretreatment strategies to break down plant material, finding or engineering microorganisms that can ferment a broader range of sugars, and improving process economics to make second-generation ethanol cost-competitive. India’s abundance of agricultural waste, from rice straw to corn stover, makes lignocellulosic ethanol an attractive target, though the technical and economic hurdles remain significant.
Beyond biofuels, Indian biotech firms are active in industrial enzymes, bioplastics, and bioremediation. Enzyme manufacturers serve both domestic and export markets, supplying textile, food processing, and detergent industries. Bioremediation research, using microorganisms to clean up contaminated soil and water, addresses a pressing need given the country’s industrial pollution challenges. These industrial applications tend to attract less public attention than medical or agricultural biotech, but they represent a substantial and growing share of the overall sector.
Bioinformatics and the Computational Edge
India’s deep bench of software engineering talent has given its bioinformatics sector a natural advantage. Bioinformatics sits at the intersection of biology and computation, and the same cities that produce large numbers of skilled programmers also feed bioinformatics labs and companies. Bangalore, Hyderabad, and Pune all have significant bioinformatics clusters.
The IndiGenomes project mentioned earlier is one example of how computational capacity translates into biological insight. But bioinformatics extends well beyond genomics. Indian teams work on protein structure prediction, drug-target interaction modeling, clinical data analytics, and the computational infrastructure that underpins precision medicine initiatives. As machine learning tools become more central to biological research globally, India’s combination of biological sample diversity and computational talent positions it well, though translating computational findings into clinical or commercial products remains the harder step.
Contract research and data analytics services for global pharmaceutical companies also form a significant part of the sector. Several Indian bioinformatics firms provide outsourced genomic analysis, clinical trial data management, and regulatory documentation services to companies worldwide, functioning as a knowledge-process outsourcing layer for the global biotech industry. This service model generates revenue and builds expertise, even if it sometimes means that the highest-value intellectual property ends up being owned abroad.